Key result
An erratum was published to correct statements regarding the protein binding of new anticoagulants for atrial fibrillation.
This is an erratum correcting statements about protein binding of new anticoagulants in a previously published article.
Clinicians must update NOAC protein binding references in AF; the correction enhances accuracy of prior trial interpretations for research.
The authors regret the following two errors published in the above article in Seminars in Thrmbosis and Hemostasis , Volume 35, Number 5: On page 515, line five of the abstract, “These drugs have minimal protein binding and predictable pharmacokinetics that allow fixed dosing without laboratory monitoring and are being compared with vitamin K antagonists or aspirin in phase III clinical trials”, is incorrect. This line should read “These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials”. On page 516, column one, under heading “New Anticoagulants”, line three, “The new anticoagulants are all small synthetic molecules with advantages that include minimal protein binding, predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring”, is incorrect. This line should read “The new anticoagulants are all small synthetic molecules with advantages that include predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring”.
No takes yet. Share an insight, caveat, or question.
Sobieraj‐Teague et al. (2009) conducted an editorial in Atrial Fibrillation. New anticoagulants vs. vitamin K antagonists or aspirin was evaluated. An erratum was published to correct statements regarding the protein binding of new anticoagulants for atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: